MX379007B - Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. - Google Patents
Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo.Info
- Publication number
- MX379007B MX379007B MX2018003832A MX2018003832A MX379007B MX 379007 B MX379007 B MX 379007B MX 2018003832 A MX2018003832 A MX 2018003832A MX 2018003832 A MX2018003832 A MX 2018003832A MX 379007 B MX379007 B MX 379007B
- Authority
- MX
- Mexico
- Prior art keywords
- prolyl hydroxylase
- alkynyl
- pyridine
- present
- preparation
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 2
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 title 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 2
- 208000007502 anemia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- -1 class of alkynyl pyridine Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510648342.9A CN105130888A (zh) | 2015-10-09 | 2015-10-09 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| PCT/CN2015/095728 WO2017059623A1 (zh) | 2015-10-09 | 2015-11-27 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018003832A MX2018003832A (es) | 2018-06-18 |
| MX379007B true MX379007B (es) | 2025-03-11 |
Family
ID=54716523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003832A MX379007B (es) | 2015-10-09 | 2015-11-27 | Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10889546B2 (enExample) |
| EP (1) | EP3360862B1 (enExample) |
| JP (1) | JP6635562B2 (enExample) |
| KR (1) | KR20180063229A (enExample) |
| CN (2) | CN105130888A (enExample) |
| AU (1) | AU2015411258B2 (enExample) |
| BR (1) | BR112018005969A2 (enExample) |
| CA (1) | CA3000040A1 (enExample) |
| DK (1) | DK3360862T3 (enExample) |
| ES (1) | ES2794002T3 (enExample) |
| HR (1) | HRP20200907T1 (enExample) |
| HU (1) | HUE049409T2 (enExample) |
| LT (1) | LT3360862T (enExample) |
| MX (1) | MX379007B (enExample) |
| PL (1) | PL3360862T3 (enExample) |
| PT (1) | PT3360862T (enExample) |
| RU (1) | RU2692494C1 (enExample) |
| SI (1) | SI3360862T1 (enExample) |
| UA (1) | UA120407C2 (enExample) |
| WO (1) | WO2017059623A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105130888A (zh) | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CN107417605A (zh) * | 2017-08-02 | 2017-12-01 | 江苏艾立康药业股份有限公司 | 作用于脯氨酰羟化酶的吡啶衍生化合物 |
| WO2019080865A1 (zh) * | 2017-10-25 | 2019-05-02 | 江苏恒瑞医药股份有限公司 | 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法 |
| CN110240562B (zh) * | 2018-03-08 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法 |
| MX2020012083A (es) * | 2018-05-24 | 2021-02-09 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Metodo de preparacion del inhibidor de alquinilpiridina prolil hidroxilasa. |
| CN109593084B (zh) * | 2019-01-23 | 2021-09-28 | 中国药科大学 | 脯氨酰羟化酶小分子光敏前药及其制备方法与应用 |
| CA3131445A1 (en) * | 2019-03-04 | 2020-09-10 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor |
| US20230295110A1 (en) * | 2020-08-14 | 2023-09-21 | Akebia Therapeutics, Inc. | Phd inhibitor compounds, compositions, and methods of use |
| CN112741834A (zh) * | 2021-02-07 | 2021-05-04 | 复旦大学附属中山医院 | HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用 |
| CN116120340B (zh) * | 2021-11-15 | 2023-10-31 | 艾立康药业股份有限公司 | 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途 |
| CN116514710B (zh) * | 2022-01-21 | 2024-07-05 | 中国药科大学 | 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4410480A1 (de) * | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PL3357911T3 (pl) * | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| WO2008076425A1 (en) * | 2006-12-18 | 2008-06-26 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| CL2008000066A1 (es) * | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| WO2011132633A1 (ja) * | 2010-04-19 | 2011-10-27 | 第一三共株式会社 | 置換５－ヒドロキシピリミジン－４－カルボキサミド化合物 |
| WO2012031298A2 (en) * | 2010-09-03 | 2012-03-08 | Duke University | Ethynylbenzene derivatives |
| KR102029951B1 (ko) | 2011-07-22 | 2019-11-08 | 베이징 베타 파머수티컬 컴퍼니 리미티드 | 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도 |
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
-
2015
- 2015-10-09 CN CN201510648342.9A patent/CN105130888A/zh active Pending
- 2015-11-27 DK DK15905721.5T patent/DK3360862T3/da active
- 2015-11-27 HR HRP20200907TT patent/HRP20200907T1/hr unknown
- 2015-11-27 AU AU2015411258A patent/AU2015411258B2/en not_active Ceased
- 2015-11-27 ES ES15905721T patent/ES2794002T3/es active Active
- 2015-11-27 PL PL15905721T patent/PL3360862T3/pl unknown
- 2015-11-27 PT PT159057215T patent/PT3360862T/pt unknown
- 2015-11-27 CN CN201580079971.2A patent/CN107848976B/zh active Active
- 2015-11-27 SI SI201531228T patent/SI3360862T1/sl unknown
- 2015-11-27 BR BR112018005969-2A patent/BR112018005969A2/pt not_active Application Discontinuation
- 2015-11-27 KR KR1020187012413A patent/KR20180063229A/ko not_active Ceased
- 2015-11-27 JP JP2018515119A patent/JP6635562B2/ja not_active Expired - Fee Related
- 2015-11-27 HU HUE15905721A patent/HUE049409T2/hu unknown
- 2015-11-27 UA UAA201804628A patent/UA120407C2/uk unknown
- 2015-11-27 MX MX2018003832A patent/MX379007B/es unknown
- 2015-11-27 LT LTEP15905721.5T patent/LT3360862T/lt unknown
- 2015-11-27 EP EP15905721.5A patent/EP3360862B1/en active Active
- 2015-11-27 US US15/765,387 patent/US10889546B2/en not_active Expired - Fee Related
- 2015-11-27 WO PCT/CN2015/095728 patent/WO2017059623A1/zh not_active Ceased
- 2015-11-27 RU RU2018113258A patent/RU2692494C1/ru active
- 2015-11-27 CA CA3000040A patent/CA3000040A1/en not_active Abandoned
-
2020
- 2020-09-11 US US17/018,221 patent/US20200407319A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017059623A1 (zh) | 2017-04-13 |
| CN105130888A (zh) | 2015-12-09 |
| LT3360862T (lt) | 2020-07-10 |
| AU2015411258A1 (en) | 2018-05-10 |
| US20180305317A1 (en) | 2018-10-25 |
| HK1247613A1 (zh) | 2018-09-28 |
| EP3360862A4 (en) | 2018-08-15 |
| DK3360862T3 (da) | 2020-06-02 |
| PL3360862T3 (pl) | 2020-09-21 |
| CA3000040A1 (en) | 2017-04-13 |
| MX2018003832A (es) | 2018-06-18 |
| JP6635562B2 (ja) | 2020-01-29 |
| AU2015411258B2 (en) | 2020-09-17 |
| KR20180063229A (ko) | 2018-06-11 |
| JP2018529690A (ja) | 2018-10-11 |
| CN107848976B (zh) | 2020-11-17 |
| HRP20200907T1 (hr) | 2020-09-04 |
| EP3360862B1 (en) | 2020-04-22 |
| ES2794002T3 (es) | 2020-11-17 |
| BR112018005969A2 (pt) | 2018-10-16 |
| HUE049409T2 (hu) | 2020-10-28 |
| US20200407319A1 (en) | 2020-12-31 |
| SI3360862T1 (sl) | 2020-08-31 |
| US10889546B2 (en) | 2021-01-12 |
| EP3360862A1 (en) | 2018-08-15 |
| CN107848976A (zh) | 2018-03-27 |
| RU2692494C1 (ru) | 2019-06-25 |
| UA120407C2 (uk) | 2019-11-25 |
| PT3360862T (pt) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379007B (es) | Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| MX2018007022A (es) | Metodos para tratar la enfermedad de huntington. | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| MX2017002206A (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| EA201791576A1 (ru) | Ингибитор jak | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| BR112017025781A2 (pt) | derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak | |
| EA201691881A1 (ru) | Новые соединения | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| MX2015013175A (es) | Derivados de cumarina y metodos de uso en el tratamiento de enfermedades hiperproliferativas. | |
| EA201490823A1 (ru) | Агенты, реверсирующие действие антикоагулянтов | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 |